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INTRODUCTION
Periostin is an extracellular matrix protein, which is produced 
by a variety of cells, and is involved in cell adhesion and con-
nective tissue regeneration. Its role in the development of car-
diovascular, respiratory, allergic, and other inflammatory dis-
eases has been postulated.1 Based on genome-wide profiling, 
the periostin gene POSTN was found to be one of the most 
highly expressed genes in bronchial epithelial cells from asth-
matics,2 and its expression in nasal polyps and chronic rhinosi-
nusitis tissue is also increased.3 Periostin is induced in airway 
epithelium and lung fibroblasts by IL-4 and IL-13, and seems to 
be a marker for Th2-inflamation and bronchial and sinonasal 
remodeling.3,4 Serum periostin in severe asthmatics was even a 
stronger predictor of airway eosinophilia compared to blood 
eosinophil count, fractional exhaled nitric oxide (FeNO), and 
total IgE.5 On the other hand, it was not possible to distinguish 
between eosinophilic and non-eosinophilic inflammation in 
mild to moderate asthmatics based on serum periostin levels.6 
Elevated serum levels of periostin are associated with the se-
verity of asthma and various asthma phenotypes, e.g. late-onset 
eosinophilic asthma,7 and nonsteroidal anti-inflammatory 
drugs (NSAIDs) exacerbate respiratory disease (NERD).8 It has 
also been documented that periostin may be associated with 
the severity and chronicity of atopic dermatitis, and possibly 
other inflammatory skin diseases.9
Collecting exhaled breath condensate (EBC) is easy to per-
form and a non-invasive method of sampling material from the 
lower airways. Several biomarkers could be found in EBC, in-
cluding reactive oxygen/nitrogen species, cytokines, and other 
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molecules, which are related to the severity of asthma and oth-
er respiratory diseases.10,11 However, measurements of periostin 
concentration in EBC have not been reported yet. 
We aimed to investigate if periostin could be detected in EBC 
collected from patients with asthma and healthy subjects. Since 
measurable concentrations were detected, we investigated pos-
sible associations of EBC and serum periostin concentrations 
with asthma control or severity, and different disease pheno-




The study included 40 asthmatic patients (22 with NSAIDs-
Exacerbated Respiratory Disease and 18 tolerating NSAIDs) 
and 17 healthy controls. Asthma was characterized by variable 
severity (from moderate to severe) and current level of control 
(only 12.5% patients had controlled asthma according to the 
Asthma Management and Prevention, Global Initiative for 
Asthma [GINA] criteria, and 75% of asthmatics had asthma ex-
acerbations during the previous year). All patients were treated 
with inhaled corticosteroids (ICS) and 7 (17.5%) also received 
oral CS. The characteristics of the asthmatic group and the 
comparison of clinical characteristic of NERD and NSAID-tol-
erant asthmatics are presented in Table. The control group con-
sisted of 17 volunteers (10 males and 7 females; mean age, 
51.8±10.54 years, with no history of chronic airway disease or 
respiratory infection during the previous 4 weeks.
All patients were recruited from our Asthma Clinic and invit-
Table. Clinical characteristics of asthmatic patients in NERD patients (n=20) and NSAIDs-tolerant asthmatics. Comparisons between categorical variables were 




















Male, n (%) 9 (22) 3 (16.7) 6 (27.3) ns 6 (37.5) 3 (12.5) ns
Mean age (year±SD) 54.9±10.6 54.9±10.9 54.9±10.7 ns 54.9±13.1 54.9±8.9 ns
Atopy, n (%) 22 (55) 13 (76.5) 9 (47.4) ns 14 (93.3) 8 (33.3) <0.001
Hypersensitivity to NSAIDs, n (%) 22 (55) 22 (100) 0 ns 8 (50) 14 (58.3) ns
FEV1 baseline (% pred; mean±SD) 73.3± 22.1 69.9±25.1 77.4±17.5 ns 70.5±22.5 75.1±22.1 ns
FEV1/FVC baseline ( mean±SD) 68.3±10.6 66.1±11.1 70.9±9.7 ns 67.9±12.4 68.5±9.6 ns
FEV1/FVC postbronchodilator (mean±SD) 72.8±10.7 70.6±11.2 75.4±10.7 ns 71.2±12.7 73.8±9.4 ns
Patients with fixed airflow limitation; n (%) 14 (35) 9 (40.9) 5 (27.8) ns 8 (50) 6 (25) ns
Current treatment
   ICS, n (%) 40 (100) 22 (100) 18 (100) ns  16 (100) 24 (100) ns
   Low dose*, n (%) 5 (12,5) 1 (4,5) 4 (22.2) ns 3 (18.75) 2 (8.3) ns
   Medium dose*, n (%) 20 (50) 11 (50) 9 (50) ns 8 (50) 12 (50) ns
   High dose dose*, n (%) 15 (37,5) 10 (45.5) 5 (27.8) ns 5 (31.25) 10 (41.7) ns
   LABA, n (%) 39 (97,5) 22 (100) 17 (94.4) ns 16 (100) 23 (95.8) ns
   Oral steroids, n (%) 7 (17,5) 6 (27.3) 1 (5.6) ns 2 (12.5) 5 (20.8) ns
   Leukotriene antagonists, n (%) 9 (22,5) 5 (22.7) 4 (22.2) ns 1 (6.25) 8 (33.3) 0.03
Asthma control and severity
   Controlled*, n (%) 5 (12.5) 3 (13.6) 2 (11.1) ns 2 (12.5) 3 (12.5) ns
   Partly controled*, n (%) 10 (25) 4 (18.2) 6 (33.3) ns 5 (31.25) 5 (20.8) ns
   Uncontrolled*, n (%) 25 (62.5) 15 (68.2) 10 (55.6) ns 9 (56.25) 16 (66.7) ns
   ACT score (mean±SD) 15.9±5.4 15.6±5.3 15.7±5.7 ns 15.7±6 16±5.2 ns
   Severe asthma†, n (%) 8 (20) 7 (31.8) 1 (5.6) 0.029 1 (6.25) 7 (29.2) ns
   Exacerbations last year, n (%) 30 (75) 17 (77.3) 13 (72.23) ns 11 (68.75) 19 (79.2) ns
FeNO (ppb; mean±SD) 36.4±16.6 42±18.5 (18-82) 29.6±11 0.016 33.2±16.4 38.6±16.7 ns
FeNO >50 ppb, n (%) 7 (17.5) 7 (31.8) 0 0.002 1 (6.25) 6 (25) ns
Positive nasal swab culture 20 (50) 13 (59.1) 7 (38.9) ns 5 (31.25) 15 (62.5) ns
*According to GINA12; †According to ATS criteria15.
NERD, NSAID-exacerbated respiratory disease; NSAIDs, Nonsteroidal anti-inflammatory drugs; FEV1, forced expiratory volume in 1 second; FEV1/FVC, forced expi-
ratory volume in 1 second % of forced vital capacity; ICS, Inhaled corticosteroids; LABA, long-acting beta-agonists; FeNO, fractional exhaled nitric oxide; CRS, Chron-
ic Rhinosinusitis.
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ed to a single visit, during which all the procedures (question-
naire, spirometry, FeNO measurement, skin prick tests, EBC 
collecting, and blood sampling) were performed. The ques-
tionnaire included questions about family history and environ-
mental factors, including smoking, concomitant chronic dis-
eases, allergic diseases, respiratory symptoms, medication load, 
and use of health services. The study was approved by the Bio-
ethics Committee of the Medical University of Lodz, and all pa-
tients signed an informed consent.
Definitions
Asthma was diagnosed according to the Global Strategy for 
the GINA 2011 criteria.12 NERD was diagnosed based on clini-
cal history, including at least 2 episodes of asthma exacerbation 
associated with NSAIDs intake and/or ASA oral challenge.13 
Asthma exacerbation was defined as the presence of at least 
one of the following events during the past 12 months: an un-
scheduled visit to the doctor’s office, a course of oral corticoste-
roids, hospitalization or emergency service intervention due to 
worsening of asthma-related symptoms. The level of asthma 
control was established according to the GINA 2011 guide-
lines12 and assessed by the Asthma Control Test14 Severe/diffi-
cult to control asthma was defined according to the ATS Work-
shop 2000 criteria.15 Chronic rhinosinusitis was diagnosed ac-
cording to the EPOS criteria (typical clinical symptoms, con-
firmed by rhinoscopy, and sinus imaging if necessary.16
Skin prick tests (SPTs)
The panel of skin prick tests (Allergopharma, Reinbek, Ger-
many) included the following allergens: Dermatophagoides 
pteronyssinus, Dermatophagoides farinae, cat, dog, tree mix, 
grass mix, weed mix, Alternaria tenuis, and Cladosporium her-
barum. A positive result was defined as a wheal of ≥3 mm in 
diameter. Atopy was diagnosed in the presence of at least 1 pos-
itive skin test.
Spirometry
Spirometry was performed according to ERS standards,17 us-
ing a Lungtest 500 spirometer (MES, Kraków, Poland). Before 
performing spirometry, patients were asked to discontinue 
long-acting beta-agonists (LABA), teophylline, and leukotriene 
receptor antagonist for 24 hours, short-acting β-agonist (SABA) 
and ipratropium bromide for 6 hours. A reversibility test after 
salbutamol inhalation (400 mcg salbutamol MDI) was per-
formed in all asthmatic patients.
FeNO measurement 
Patients underwent online single breath maneuvers accord-
ing to ATS/ERS guidelines18 using the HypAir FeNO (Medisoft, 
Belgium). The mean value of at least 2 successful measure-
ments was analyzed. FeNO measurement was performed be-
fore spirometry and EBC collecting. 
Collection of EBC 
EBC samples were collected using TURBODECCS 09 unit 
(Medivac, Parma, Italy) according to the manufacturer’s in-
structions and ERS/ATS recommendations.19 Patients were 
asked to breath tidally for 10 minutes through the mouthpiece 
with a saliva trap in the sitting position. The temperature of the 
condenser was set at -10°C. The respiratory samples were im-
mediately stored at -80°C and kept frozen until analysis. The 
collection of EBC was performed before spirometry and after 
FeNO measurement. 
Nasopharyngeal secretions and bacterial cultures 
Nasopharyngeal samples for the detection of bacteria were 
collected using swabs flocked with soft nylon fiber (Copan, Ita-
ly). The swabs were transported to the Microbiology Laborato-
ry in Amies transport medium and inoculated on selective and 
non-selective media no longer than 2 hours after collection. 
The plates were evaluated 24 and 48 hours after inoculation for 
the presence of Streptococcus pneumoniae, Moraxella catarrh-
alis, Haemophilus influenzae, Haemophilus parainfluenzae, 
Staphylococcus aureus, and Streptococcus pyogenes.
Periostin measurements in EBC and serum
Periostin was measured in the sera and in the EBC using an 
enzyme-linked immunoassay (R&D Systems, Minneapolis, 
MN, USA) according to the manufacturer’s instructions. 
Statistical analysis
Categorical variables were compared using the chi-square 
test. Quantitative variables are presented as means and stan-
dard deviation and compared using unpaired t-tests. Continu-
ous variables were compared using Pearson’s correlation. The 
statistical analysis was performed using Statistica (StatSoft, Tul-
sa, OK, USA). P values <0.05 were accepted as statistically sig-
nificant. 
RESULTS
Detectable concentrations of periostin were found in EBC 
samples from 37/40 asthmatics and in 16/17 healthy subjects. 
Periostin was detected in the sera of all study participants. The 
mean periostin level was lower in EBC samples than in serum 
(2.9±1.7 vs 24.6±11.3 ng/mL; P<0.001). There were no differ-
ences in EBC or serum periostin concentrations between asth-
ma patients and control subjects (Fig. 1). No correlation be-
tween EBC and serum periostin concentrations was found in 
the entire group of asthmatic patients or in the control group. 
Periostin in EBC 
Periostin concentrations in EBC were not related to asthma 
severity, asthma control, intensity of ICS treatment, lung func-
tion, or presence of fixed airflow limitation defined as lack of re-
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versibility to salbutamol (data not shown). There was no rela-
tionship between periostin levels in EBC and age/sex/presence 
of atopy. 
However, in asthmatic patients with diagnosis of chronic rhi-
nosinusitis (CRS), who reported sinonasal symptoms during 
the previous 3 months (n=24), periostin levels in EBC were sig-
nificantly higher in subjects without CRS symptoms than in 
those without (3.1±1.7 vs 2±1.6 ng/mL, P=0.046) (Fig. 2A). 
Twenty of 40 patients with asthma had positive bacterial cul-
tures from nasal swabs and the most common bacteria were 
Staphylococcus aureus (n=14) followed by Streptococcus pneu-
moniae (n=5), Haemophilus influenza (n=5), Haemophilus 
parainfluenzae (n=5), and Streptococcus pyogenes (n=5). Asth-
matic patients with positive bacterial cultures from nasal swabs 
had higher levels of periostin in EBC than patients with nega-
tive cultures (3.2±2 vs 2.1±1.2 ng/mL; P=0.037) (Fig. 2B).
Serum periostin levels 
The mean serum periostin concentrations were significantly el-
evated in asthmatics who reported an exacerbation and/or re-
quired unscheduled doctor office visit within the previous 12 
months, as compared to those without (27±11.5 vs 19.5±10.1 
ng/mL, P=0.036). Patients treated with leukotriene antagonist 
added to ICS had a significantly lower serum periostin level 
(16.2±10.5 vs 25.6±10.9 ng/mL, P=0.028). A positive correla-
tion between serum periostin and FeNO levels (r=0.33; P=0.039) 
was found, and asthmatics with a very high FeNO level (over 50 
ppb) had a higher serum periostin level than subjects with a low-
er FeNO (35.1±4.4 vs 21±10.9 ng/mL; P=0.002) (Fig. 3A). 
For all groups of asthmatics, there was no relationship be-
tween periostin levels in serum and age/sex/presence of atopy/
asthma severity, intensity of ICS treatment, lung function/air-
way reversibility after bronchodilator nebulization. 
Mean periostin concentrations in serum were similar in NERD 
patients and NSAIDs-tolerant asthmatics (26.5±10.7 vs 19.7±
11.5 ng/mL; ns). However, NERD patients with history of asth-
ma exacerbation within last 12 months (n=17) had significantly 
higher mean serum periostin level as compared to those with-
Fig. 1. Periostin concentrations (ng/mL) in EBC (A) and serum (B) of asthmatics, and healthy controls (differences are not statistically significant). Data are presented 














































Fig. 2. Periostin concentration (ng/mL) in EBC (A) from asthmatics with and without chronic rhinosinusitis symptoms in the previous 3 months and (B) from asthmat-
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out (n=5), (29.4±8.5 vs 16.5±12.1 ng/mL; P=0.013). There was 
also a stronger correlation between serum periostin concentra-
tion and FeNO level in all groups (r=0.59; P<0.004) (Fig. 3B).
NERD patients, who reported skin symptoms (urticaria and/or 
angioedema) after NSAIDs intake in addition to bronchial ob-
struction (n=16), had higher levels of serum periostin than 
those with only bronchial symptoms after NSAIDs and NSAIDs-
tolerant asthmatics (n=24), (29.2±9.7 vs 19.6±11 ng/mL; 
P=0.007). 
DISCUSSION
This is the first study reporting detectable concentrations of 
periostin in EBCs-biological material that is considered to 
originate from lower airways. Concentrations of periostin were 
similar in EBC, as well as in serum, collected from patients with 
asthma and healthy individuals, which is difficult to explain be-
cause in previous studies increased levels of this molecule have 
been found in induced sputum and were associated with eo-
sinophilic airway inflammation.20 It seems likely that EBC and 
serum levels of periostin in our asthma patients were affected 
by chronic asthma treatment. All patients received inhaled cor-
ticosteroids and majority of them (87.5%) were on medium or 
high doses of ICS. It has previously been shown that steroid-na-
ïve patients had a 10% reduction in serum periostin level after a 
48-week treatment with ICS21 and periostin gene (POSTN) ex-
pression in the airway epithelium is decreased following ICS 
therapy2 In addition, 17% of our asthma patients were treated 
with systemic corticosteroids, which may have reduced perios-
tin concentration in the serum of asthmatic patients.22 We also 
observed that 9 patients treated with leukotriene antagonist 
added to ICS had a significantly lower serum periostin level 
than those treated with ICS only, which suggests that the inten-
sity and/or the type of anti-inflammatory treatment may influ-
ence serum concentrations of periostin.
The EBC periostin level was not correlated with parameters of 
asthma control and severity, and lung function or FeNO levels, 
suggesting that it may not reflect lower airway inflammation. 
This is in contrast to studies assessing periostin in induced spu-
tum, which demonstrated the association of periostin levels 
with asthma severity or the presence of fixed bronchial obstruc-
tion as well as with the percentage of eosinophils in the blood 
and sputum20,23 However, our asthmatic patients with CRS who 
reported symptoms during the previous 3 months had on aver-
age 50% higher levels of periostin in EBC than those without. 
Patients with and without CRS symptoms were similar with re-
spect to all clinical/pathophysiological features of asthma, in-
cluding severity, asthma control, or spirometry. These observa-
tions strongly point at differences in upper airway inflamma-
tion type or intensity as the source of differences in EBC perios-
tin levels.  Although EBC is considered to sample primarily low-
er airways, it may also contain proteins and other particles de-
rived from the upper respiratory tract10 Using EBC collection set 
with a saliva trap, a 1-way valve, and a nasal clip, we attempted 
to avoid sampling from the upper airways, but contamination 
with the upper airway fluid could not be completely avoided. 
Thus, it is likely that at least part of periostin in EBC originated 
from inflamed upper airways. Periostin was previously detect-
ed in nasal lavage fluids, and an increased expression of perios-
tin in sinonasal mucosa was observed in patients with CRS and 
polyps or with allergic rhinitis3 which indicated that upper air-
ways may be a substantial source of this mediator, and this mol-
ecule has been implicated in the pathogenesis of CRS.3,24,25 
These observations are also in line with previously reported in-
creased periostin levels in the sera of asthmatics with concomi-
tant nasal disorders.26 Interestingly, patients with positive bac-
terial cultures from nasopharyngeal secretions had higher lev-
els of periostin in EBC than those without. Bacterial infections 
may exacerbate CRS, and host-microbial interactions seem to 
be important for the pathogenesis of the sino-nasal disease.27 
Fig. 3. Correlation between levels of periostin and FeNO inserum (A) in the entire group of asthmatics (r=0.33; P=0.039) and between (B) levels of FeNO in exhaled 
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Our findings suggest that the presence of bacteria in the upper 
airways, even without evident symptoms of acute infections, 
may increase local production and/or release of periostin, 
which is in turn detected in the EBC. Thus, it appears that peri-
ostin in EBC may originate from both lower and upper airways, 
which may explain lack of correlations with FeNO or asthma 
severity/control.
In contrast to EBC, a positive correlation between serum peri-
ostin and FeNO was observed, and higher mean periostin se-
rum concentrations in patients with very high (above 50 ppb) 
FeNO level were detected. These observations are in line with 
those of previous reports documenting association of periostin 
levels in serum with FeNO levels6 or with blood and sputum eo-
sinophilia20 in asthmatic patients. The serum periostin level has 
been even proposed as a surrogate marker for Th2-inflamma-
tion driven by IL 13, and the serum periostin level has been 
proposed as a better marker for airway eosinophilia than blood 
eosinophilia.5 Furthermore, our patients with a history of asth-
ma exacerbation in the past 12 months had higher levels of 
periostin than those without. Similarly, Scichilone et al.28 found 
that serum periostin level was a predictor of asthma exacerba-
tion at a 1-year follow-up. 
EBC concentrations of periostin were significantly lower as 
compared to serum levels, which is in line with previous stud-
ies reporting lower periostin levels in induced sputum20,23 and 
bronchial lavage fluid (BLF)29 than in the serum. In the studies 
analyzing induced sputum, the concentration of periostin was 
above the lower limit of detection of the immunoassays 
used,20,23 and periostin could be detected in BLF only in the 
samples with 10-fold concentration.29 Most of our study sub-
jects (37/40 of asthmatics and 16/17 controls) had EBC perios-
tin levels above the lower detection limit of the immunoassay 
used. We did not find any correlation between serum and EBC 
periostin concentrations. Similarly, Simpson et al.23 reported no 
associations between serum and IS periostin levels. 
NERD represents asthma phenotype with higher than aver-
age disease severity, complicated by CRS with nasal polyps and 
characterized by severe eosinophilic inflammation in both up-
per and lower airways.30,31 It has been reported that serum peri-
ostin level is associated with NERD phenotype, and correlates 
with blood eosinophil counts and sputum eosinophilia.8 In our 
group, more NERD patients had severe asthma as compared to 
NSAIDs–tolerant asthmatics (31.8% vs 5,6%), and average 
NERD patients had higher mean FeNO, reflecting ongoing 
more intense bronchial inflammation. Although NERD pa-
tients from our study group had only insignificantly higher se-
rum periostin concentrations as compared to NSAIDs-tolerant 
asthmatics, those with a history of asthma exacerbation within 
the last 12 months had significantly higher mean serum perios-
tin levels as compared to those without. Furthermore, NERD 
patients, who in addition to respiratory symptoms developed 
skin manifestations following NSAIDs, on average showed sig-
nificantly higher serum periostin levels. Periostin has been 
shown to be highly expressed in the skin and serum periostin 
levels were associated with inflammatory skin diseases.9 Thus, 
our observations suggest a possible association of periostin 
with a subtype of NERD phenotype, further pointing at patho-
physiological heterogeneity of this group of asthmatics.30 
In summary, we demonstrated that periostin was detectable 
in EBC from both asthma patients and healthy subjects, but 
periostin EBC concentrations did not show any correlation with 
asthma parameters. However, increased periostin levels in EBC 
were associated with symptoms of CRS and positive nasopha-
ryngeal bacterial cultures, which can suggest that inflamed up-
per airways may be a source of periostin. In contrast, periostin 
levels in serum were associated with some asthma activity 
markers (history of exacerbations or FeNO) or NERD subphe-
notypes, indicating that the source of the biological material, in 
which periostin is measured, may determine the utility of peri-
ostin as a biomarker for asthma. 
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